Table 2.
Outcome/variables | Selection method | β coefficient (95% CI) | P-value |
---|---|---|---|
Change in serum phosphateb | |||
Treatment: FC versus placebo | Fixed | −0.21 (−0.38 to −0.05) | 0.012 |
Serum phosphate, mg/dL | Fixed | −0.58 (−0.69 to −0.47) | <0.001 |
eGFR, mL/min/1.73 m2 | Stepwise AIC | −0.01 (−0.02 to −0.01) | <0.001 |
Albumin, g/dL | Stepwise AIC | −0.26 (−0.47 to −0.04) | 0.023 |
Change in cFGF23c,d | |||
Treatment: FC versus placebo | Fixed | −33.8 (−46.3 to −21.3) | <0.001 |
cFGF23b | Fixed | −0.57 (−0.69 to −0.45) | <0.001 |
Age, years | Stepwise AIC | −0.86 (−1.41 to −0.32) | 0.002 |
Diabetes: yes versus no | Stepwise AIC | −16.2 (−30.3 to −2.1) | 0.025 |
eGFR, mL/min/1.73 m2 | Stepwise AIC | −1.53 (−2.07 to −0.99) | <0.001 |
Change in iFGF23c,e | |||
Treatment: FC versus placebo | Fixed | −30.2 (−44.4 to −15.9) | <0.001 |
iFGF23b | Fixed | −0.42 (−0.61 to −0.23) | <0.001 |
Sex: male versus female | Stepwise AIC | 17.7 (3.1–32.3) | 0.018 |
Race: non-white versus whitef | Stepwise AIC | 24.4 (9.1–39.8) | 0.002 |
eGFR, mL/min/1.73 m2 | Stepwise AIC | −1.03 (−1.78 to −0.28) | 0.008 |
Serum phosphate, mg/dL | Stepwise AIC | −8.5 (−19.1–2.2) | 0.122 |
Log cFGF23 | Stepwise AIC | 7.0 (−1.5–15.6) | 0.109 |
Missing data were imputed using the last observation carried forward method.
Sensitivity analyses demonstrated stable associations, irrespective of the method for missing data handling or multivariable model selection (Supplementary data, Tables S1 and S2).
Owing to non-normal distribution of FGF23, rank transformations were employed.
Sensitivity analyses demonstrated similar associations among different methods for missing data handling or multivariable model selection (Supplementary data, Tables S3 and S4).
Sensitivity analyses demonstrated similar associations across most methods for missing data handling or multivariable model selection (Supplementary data, Tables S5 and S6).
Of the non-white category, 94.5% were Black or African American.
FC, ferric citrate.